FactorPad
Build a Better Process

Stock Risk Measures for Iovance Biotherapeutics Inc

A quantitative factor review as of September 30, 2021.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
face pic by Paul Alan Davis, CFA
Updated: October 05, 2021
See how we arrive at an overall risk score of 75 for IOVA below.

/ factorpad.com / stocks / f29bqp.html


An ad-free and cookie-free website.


IOVA Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Iovance Biotherapeutics Inc. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how IOVA stock compares to 2,000+ US-based stocks, and to peers in the Manufacturing sector and Biological Product (except Diagnostic) Manufacturing industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy uses a patient's own immune cells to attack cancer. TIL cells are extracted from a patient's own tumor tissue, expanded through a proprietary process, and infused back into the patient. Upon infusion, TIL reach tumor tissue, where they attack cancer cells. The company has completed dosing in pivotal programs in patients with metastatic melanoma and cervical cancer. In addition, the company's TIL therapy is being investigated in a registration-supporting study for the treatment of patients with locally advanced, recurrent or metastatic non-small cell lung cancer. Clinical studies are also underway to evaluate TIL in earlier stage cancers in combination with currently approved treatments, and to investigate Iovance peripheral blood lymphocyte (PBL) T cell therapy for blood cancers.

Identity

Sector and Industry

Share Data

Shares

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f29bqp.html


IOVA stock risk
IOVANCE BIOTHERAPEUTICS INC stock beta
IOVA risk report
IOVA f29bqp
IOVA risk analysis
IOVA volatility
IOVANCE BIOTHERAPEUTICS INC credit risk
IOVA liquidity risk
IOVA leverage
IOVA valuation
IOVA systematic risk
IOVA specific risk
IOVANCE BIOTHERAPEUTICS INC volatility
IOVA analysis
IOVA financial ratio

A newly-updated free resource. Connect and refer a friend today.